The present study was undertaken to investigate the predictors in patients who received hormonal therapy (HT) for prostate-specific antigen recurrence (PSAR) after surgery. Predictors for the progression-free survival were assessed in 55 patients who received HT for PSAR after surgery. In multivariate analysis, primary Gleason grade !4 and PSA doubling time (PSA-DT) ,6 months were independent predictors. The patients were stratified into low-risk group (Gleason grade ,4 and PSA-DT !6), high-risk group (Gleason grade !4 and PSA-DT ,6) and intermediate-risk group (all others). In the intermediate-and high-risk groups, progression-free survival rate was significantly higher in patients with PSA level ,2 than in those with PSA level !2 at the initiation of HT. Primary Gleason grade !4 and PSA-DT ,6 months are independent predictors. Patients in the intermediate-and high-risk groups may benefit from early HT for PSAR after surgery.
INTRODUCTION
The incidence of clinically localized prostate cancer has dramatically increased and radical prostatectomy (RP) has become an established form of curative therapy since the introduction of prostate-specific antigen (PSA) examination. However, $40% of patients with clinically localized disease will experience prostate-specific antigen recurrence (PSAR) after surgery (1 -5) . Treatment for PSAR after RP is controversial. Localized therapies such as salvage radiation are best reserved for men with a high likelihood of having confined disease (6) . Hormonal therapy (HT) is commonly used for the management of PSAR. However, there has been little published literature about this intervention.
Risk stratification is an important issue in cancer treatment because it can facilitate a more accurate prediction of outcome and provide a more homogenous population for the most appropriate therapeutic approach. However, to our knowledge, no previous investigation has attempted to set up a risk stratification model based on a multivariate analysis in patients treated with HT for PSAR after RP alone.
In recent years, as the number of RP increases, urologists are frequently confronting PSA failure after surgery. Therefore, the management of patients with the PSA failure is one of our major concerns. Since there is no English literature about it in Japan, to our knowledge, the study of HT for PSAR is definitely and urgently needed.
The present study was undertaken to investigate the prognostic factors for biochemical progression in patients treated with HT for PSAR after RP and to develop a prognostic factor-based model for risk stratification of HT for PSAR after RP. This would be the first report to investigate the prognostic factors including PSA doubling time (PSA-DT) in Japanese patients treated with HT for PSAR after RP and to develop a risk stratification of HT for PSAR after RP alone. PSA at diagnosis and PSA when HT was started were 14.9 + 9.9 and 6.2 + 1.7, respectively. In the pathological examination, 34 patients had extracapsular invasion, 11 had seminal vesicle invasion and 31 had lymphovascular invasion. Surgical margins were positive in 25 patients.
PATIENTS AND METHODS
As a first-line HT, 20 patients received an oral antiandrogen, 31 received luteinizing hormone-releasing hormone (LH-RH) agonist alone and 4 received maximum androgen blockade (MAB). All patients who initially received anti-androgen monotherapy or LH-RH agonist monotherapy and then showed failure of the initial treatment finally received MAB.
Patients were followed post-operatively with clinical laboratory studies every 3 months after surgery. The mean follow-up period after surgery was 77.2 + 6.0 months and the median follow-up period after surgery was 72 months (range, 12 -170 months). PSA-DT was calculated, assuming first-order kinetics as reported previously (7) . The minimum PSA value used to calculate the PSA-DT needed to be .0.2 ng/ml for all study patients. DT was determined per patient by calculating the logarithm of PSA values.
Biochemical progression was defined as three consecutive rises in PSA levels after MAB. The tumor was staged according to the 1997 TNM classification (8) .
Prognostic factors assessed included age, PSA at diagnosis, PSA at the initiation of HT, PSA-DT, the duration between surgery and PSAR, initial treatment and histological findings of surgical specimens including primary Gleason grade, Gleason score, extracapsular extension, seminal vesicle invasion, surgical margin, pathological nodal involvement and lymphovascular invasion. Gleason grade and score of prostatectomy specimens were cited from medical records.
Survival curves were constructed by the Kaplan -Meier method. Univariate risk factor analysis was performed by the log-rank test and multivariate analysis by Cox's regression.
To obtain a multivariate model with the maximum precision of the important variables, a stepwise selection procedure was used. As reported previously (9), continuous pretreatment clinical measurements were analyzed as dichotomous variables according to approximately 'optimal' cutpoints as follows. The value best discriminating between good and poor survival (i.e. which had the most significant P value on a log-rank test) was found by testing all possible cutpoints. All such cutpoints were then rounded to clinically relevant (i.e. convenient) values. Using the statistically significant variables in the multivariate Cox regression analysis, the relative risk of PSA progression could be calculated using the formula, exp (parameter estimate of the statistically significant variable in multivariate analysis), as described previously (10, 11) . In all analyses, P , 0.05 was considered statistically significant.
RESULTS
The 5-and 10-year biochemical progression-free survival rates were 88.3% and 71.3%, respectively.
In univariate analysis, primary Gleason grade !4, PSA-DT ,6 months and late HT (PSA when HT was started !2.0 ng/ml) were significantly associated with biochemical progression. Among 55 patients, 20 patients had primary Gleason grade !4, 25 had PSA-DT ,6 months and 23 had PSA !2.0 ng/ml when HT was started.
Multivariate analysis revealed that primary Gleason grade !4 and PSA-DT ,6 months were independent predictors for biochemical progression (Table 1 ). According to Table 1 , the relative risk of primary Gleason grade was 7.070 and that of PSA-DT was 7.733. As described in the Patients and methods section, using the two statistically significant variables ( primary Gleason grade and PSA-DT) in the multivariate Cox regression analysis, the relative risk of PSA progression could be calculated using the formula, exp (1.956 Â primary Gleason grade þ 2.045 Â PSA-DT). In this equation, the primary Gleason grade equaled 1 if the primary Gleason grade was 4 or 5, and 0 if the primary Gleason grade was 3. PSA-DT equaled 1 if PSA-DT was ,6 months and 0 if PSA-DT was !6 months. Based on the relative risk of PSA progression, patients treated with HT for PSAR after RP were divided into three risk groups: low (relative risk of PSA progression ¼ 1), intermediate (7.070 -7.733 ) and high (54.67).
There were significant differences in the biochemical progression-free survival rate among the groups; P ¼ 0.043 for low-vs. intermediate-risk group, P , 0.001 for low-vs. high-risk group and P ¼ 0.007 for intermediate-vs. high-risk group (Fig 1A) .
Among patients in the intermediate-and high-risk groups, the biochemical progression-free survival rate after the initiation of HT was significantly higher in patients with PSA level ,2 ng/ml at the initiation of HT than in those with PSA level !2 ng/ml at the initiation of HT (Fig 1B) .
DISCUSSION
The present study was undertaken to review our single-center experience with prostate cancer patients treated with HT for PSAR after RP and to investigate predictors of biochemical progression.
It was reported that biochemical progression after HT for PSAR following initial treatment had potential as a surrogate
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Prognostic factors in patients who received HT for PSAR for impending prostate cancer death because all patients dying after biochemical progression after HT for PSAR following initial treatment died of prostate cancer within 4 years after biochemical progression after HT (12) . Therefore, in the present study, biochemical progression after MAB therapy for PSAR following surgery was used as an endpoint. Moul and co-workers (5) reported that early HT was associated with delayed clinical metastasis in patients who experienced PSAR after RP with pathological Gleason sum .7 or PSA-DT of 12 months, and that early HT did not have an impact overall. Thus, their findings indicated that the Gleason score and PSA-DT were associated with the prognosis of patients treated with HT for PSAR after RP. However, in their study, multivariate analysis including PSA-DT and Gleason score as predictors was not performed. In the present study, we have evaluated prognostic factors by multivariate analysis and developed a risk stratification model.
Messing et al. (13) conducted a randomized, multicenter trial of early vs. delayed HT in men who underwent RP and had pelvic lymph node metastasis. According to their report, early HT was significantly associated with progression-free survival, disease-specific survival and overall survival in patients with lymph node metastasis.
Our study revealed that the primary Gleason grade, PSA-DT and late HT were significantly associated with biochemical progression in univariate analysis, and that primary Gleason grade and PSA-DT were independent predictors for biochemical progression in multivariate analysis. It was reported that the association between pathological features and clinical metastasis-free survival in patients treated with HT for PSAR was analyzed and non-curable disease (the capsule was positive and Gleason score was .6, or the surgical margins, lymph nodes or seminal vesicle were positive) was an independent predictor of clinical metastasis in patients treated with HT for PSAR (7) . In the present study, Gleason grade was significantly associated with biochemical progression but no significant association was found between other pathological features and biochemical progression in patients treated with HT for PSAR.
To our knowledge, there has been no report about the appropriate type of HT for PSAR after RP. In the present study, there were some types of initial HTs, which might have affected the progression-free survival after MAB. Therefore, the multivariate Cox regression analysis including the type of initial HT was performed to evaluate the predictors of biochemical progression. No significant difference in progression-free survival was found between patients who were initially treated with an LH-RH agonist and those who were not.
The prognostic information for predicting biochemical progression in patients treated with HT for PSAR after RP might help us select a subgroup of patients who would benefit from appropriate treatment, subsequently reducing metastasis and improving disease-specific survival. Based on our results, early HT would be of benefit to reduce biochemical progression in intermediate-and high-risk groups. Recently, Kibel et al. (14) reported that progression-free survival in patients with high-risk prostate cancer after RP who received adjuvant docetaxel chemotherapy was significantly longer than that in those without adjuvant chemotherapy. Thus, another treatment, especially chemotherapy, might be an option for patients in high-risk groups.
CONCLUSION
In the present study, primary Gleason grade of !4 and PSA-DT ,6 months are independent prognostic factors for biochemical progression-free survival in patients treated with HT for PSAR after surgery. The risk stratification of biochemical progression using the primary Gleason grade and PSA-DT would be helpful for selecting a subgroup of patients who may benefit from appropriate treatments. Based on our results, early HT would be of benefit to reduce biochemical progression in high-and intermediate-risk groups.
